These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21905034)

  • 1. Stable dry powder formulation for nasal delivery of anthrax vaccine.
    Wang SH; Kirwan SM; Abraham SN; Staats HF; Hickey AJ
    J Pharm Sci; 2012 Jan; 101(1):31-47. PubMed ID: 21905034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthrax vaccine powder formulations for nasal mucosal delivery.
    Jiang G; Joshi SB; Peek LJ; Brandau DT; Huang J; Ferriter MS; Woodley WD; Ford BM; Mar KD; Mikszta JA; Hwang CR; Ulrich R; Harvey NG; Middaugh CR; Sullivan VJ
    J Pharm Sci; 2006 Jan; 95(1):80-96. PubMed ID: 16315230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.
    Huang J; Mikszta JA; Ferriter MS; Jiang G; Harvey NG; Dyas B; Roy CJ; Ulrich RG; Sullivan VJ
    Hum Vaccin; 2007; 3(3):90-3. PubMed ID: 17375001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.
    Klas SD; Petrie CR; Warwood SJ; Williams MS; Olds CL; Stenz JP; Cheff AM; Hinchcliffe M; Richardson C; Wimer S
    Vaccine; 2008 Oct; 26(43):5494-502. PubMed ID: 18703110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability and pre-formulation development of a plant-produced anthrax vaccine candidate.
    Jones RM; Burke M; Dubose D; Chichester JA; Manceva S; Horsey A; Streatfield SJ; Breit J; Yusibov V
    Vaccine; 2017 Oct; 35(41):5463-5470. PubMed ID: 28117174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.
    Wagner L; Verma A; Meade BD; Reiter K; Narum DL; Brady RA; Little SF; Burns DL
    Clin Vaccine Immunol; 2012 Sep; 19(9):1465-73. PubMed ID: 22815152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
    Garmise RJ; Staats HF; Hickey AJ
    AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.
    Mikszta JA; Sullivan VJ; Dean C; Waterston AM; Alarcon JB; Dekker JP; Brittingham JM; Huang J; Hwang CR; Ferriter M; Jiang G; Mar K; Saikh KU; Stiles BG; Roy CJ; Ulrich RG; Harvey NG
    J Infect Dis; 2005 Jan; 191(2):278-88. PubMed ID: 15609239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR; Cui Z
    Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.
    Domínguez-Castillo RI; Verma A; Amador-Molina JC; Sirota L; Arciniega JL
    Biologicals; 2013 Mar; 41(2):111-4. PubMed ID: 23137818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized Intratracheal Inoculation of Recombinant Protective Antigen (rPA) Vaccine Provides Protection Against Inhalational Anthrax in B10.D2-Hc
    Song X; Zhang W; Zhai L; Guo J; Zhao Y; Zhang L; Hu L; Xiong X; Zhou D; Lv M; Yang W
    Front Immunol; 2022; 13():819089. PubMed ID: 35154137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.
    Gauthier YP; Tournier JN; Paucod JC; Corre JP; Mock M; Goossens PL; Vidal DR
    Infect Immun; 2009 Mar; 77(3):1197-207. PubMed ID: 19114543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.
    Gwinn WM; Johnson BT; Kirwan SM; Sobel AE; Abraham SN; Gunn MD; Staats HF
    Vaccine; 2013 Mar; 31(11):1480-9. PubMed ID: 23352329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.
    Chichester JA; Manceva SD; Rhee A; Coffin MV; Musiychuk K; Mett V; Shamloul M; Norikane J; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2013 Mar; 9(3):544-52. PubMed ID: 23324615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
    Peachman KK; Li Q; Matyas GR; Shivachandra SB; Lovchik J; Lyons RC; Alving CR; Rao VB; Rao M
    Clin Vaccine Immunol; 2012 Jan; 19(1):11-6. PubMed ID: 22089245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.